standard dose of HCQ
ApprovedSmall molecule
standard dose of HCQ is one of 65 small molecule programs targeting Kidney Transplant. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1standard dose of HCQ
UUniversity of Sao Paulo General Hospital
Approved
Nulojix
Bristol-Myers SquibbPreclinical
Medrol
PfizerPreclinical
Zinbryta
RochePreclinical
Zemplar
AbbViePreclinical
Cysteine Hydrochloride
NovartisPreclinical
Radicava
ShionogiPreclinical
Jardiance
Boehringer IngelheimPreclinical
Acupan
YYonsei University
Preclinical
Cytovene
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for standard dose of HCQ. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details